Company Overview and News

182
Your Daily Pharma Scoop: Selecta Bio Reports Positive, Acceleron And Atara Moves Up On Positive Data

14h seekingalpha
Selecta Biopharma (SELB) recently presented more data from Phase 2 clinical trial of its lead candidate SEL-212 (SVP-Rapamycin + pegsiticase) in chronic severe gout. In this trial 27 patients were inducted. 81% of the patient group had a clearly marked lower level of uric acid after three months of drug administration. This extended data is a definite improvement over data from earlier Phase 2 data in which 19 patients were evaluated and 75% of them had a clearly low level of uric acid after a similar 3-month duration.
BLUE KPTI TEVA EPZM TEVVF WM GBT XLRN ATRA RDY TEVJF BGNE BLUE

140
Biotech Leadership Transformations: Week of May 28th

2018-06-04 biospace
There have been a number of leadership changes in the life sciences industries over the past week. BioSpace compiled a roundup of the changing landscape of the c-suite and boards of directors across the industry.
LPTX DCPH XLRN ARCT ALXN ADHD ICPT ELN KITE ACHN CMTA

93
5 Reasons Why Celgene Will Recover

2018-06-01 seekingalpha
Celgene (NASDAQ:CELG) is a large cap, well-known leading biotechnology company that has seen its shares fall from as high at $147.17 to as low as $74.13 in the last year. I see more than five reasons Celgene's stock price will recover. I will curate just the five I see as most important in this article. This will not be my usual balanced article, given that Celgene has received plenty of negative press lately.
XLRN GILD JUNO INCY CELG NVS BLUE

68
Biotech Leadership Transformations: Week of May 21

2018-05-29 biospace
There have been a number of leadership changes in the life sciences industries over the past week. BioSpace compiled a roundup of the changing landscape of the c-suite and boards of directors across the industry.
4503 ALPMY XLRN ALXN XON ALPMF CTMX HNSN FPRX DMPI CMTA

103
Scholar Rock IPO: I Will Wait Until 2020

2018-05-23 seekingalpha
With three product candidates in the pipeline, at a very early stage, Scholar Rock will need a long time to see the FDA approving them. That said, the company has many patents, a licence with Janssen Biotech, and a fantastic team of professionals. While the risk may be too high for the individual investors, the institutional traders must have a look at it.
REGN PFZ XLRN BIIB DYAX NVS 500680 PFE PFIZER ALNY

2
Acceleron Pharma's (XLRN) CEO Habib Dable on Q1 2018 Results - Earnings Call Transcript

2018-05-14 seekingalpha
Good afternoon, ladies and gentlemen, and welcome to the Acceleron First Quarter 2018 Earnings Conference Call. At this time, all participants are in a listen-only mode. Later, we will conduct a question-and-answer session and instructions will be given at that time. As a reminder, this conference call is being recorded.
XLRN

2
XLRN / Acceleron Pharma Inc. 10-Q (Quarterly Report)

2018-05-08 sec.gov
Document Table of Contents UNITED STATES
XLRN

245
A Fresh Look At Celgene After Q1 And New Info On Ozanimod

2018-05-08 seekingalpha
The company's sales growth is stellar, but pipeline and management issues are weighing on it, plus biotech's known big-picture concerns.
XLRN GILD JUNO GOOGL CELG AGIO AAPL BGNE

37
NewLink Genetics' (NLNK) CEO Charles Link on Q1 2018 Results - Earnings Call Transcript

2018-05-04 seekingalpha
Good afternoon, ladies and gentlemen, and welcome to the NewLink Genetics First Quarter 2018 Earnings Conference Call. At this time, all participants are in a listen-only mode. Later, we will conduct a Q&A answer session and instructions will follow at that time. [Operator Instructions] As a reminder, this conference call is being recorded.
NLNK MDGL XLRN SNTA REGI

54
2 Attractive Biotech Stocks To Buy Now

2018-05-02 seekingalpha
Today, we look at two small biotech stocks that look well positioned as we start the trading month of May.
WFC WFCNP WFC.WS FLXN WFC.PRL WFC.PRJ OA WFC.PRT WFC.PRR XLRN WFC.PRQ WFC.PRP WFC.PRO WFC.PRN WFC.PRY WFC.PRX WFC.PRW WFC.PRV

2
Acceleron Snags Fast Track Designation for FSHD Therapy ACE-083

2018-05-01 biospace
Acceleron Pharma Inc. announced its experimental facioscapulohumeral muscular dystrophy (FSHD) treatment ACE-083 garnered the Fast Track designation from the U.S. Food and Drug Administration.
XLRN

Related Articles

ARWR: Arrowhead Pharmaceuticals Analysis and Research Report

21h - Asif

Business Arrowhead develops medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and efficient modes of delivery, Arrowhead therapies trigger the RNA interference mechanism to induce rapid, deep and durable knockdown of target genes. RNA interference, or RNAi, is a mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of a specific protein. Deemed to be one of the most important recent discoveries in life science with the potential to transform medicine, the discoverers of RNAi were awarded a Nobel Prize in 2006 for their work. Arrowhead’s RNAi-based therapeutics leverage this natural pathway of gene silencing. In fiscal 2017, Arrowhead refocused its resources on therapeutics that exclusively utilize the company’s Targeted RNAi Molecule (TRiMTM) platform technology. Therapeutics built on the TRiMTM platform have demonstrated high levels of pha...

PRTO: Proteon Therapeutics Analysis and Research Report

2018-06-11 - Asif

Overview Proteon Therapeutics is a late-stage biopharmaceutical company focused on the development of novel, first-in-class pharmaceuticals to address the needs of patients with renal and vascular disease. The company's product candidate, vonapanitase, is a recombinant human elastase that Proteon Therapeutics is developing to improve vascular access outcomes in patients with chronic kidney disease, or CKD, undergoing or planning for hemodialysis, a lifesaving treatment that cannot be conducted without a functioning vascular access. The company believe data from its completed Phase 2 and Phase 3 clinical trials of vonapanitase support that a one-time, local application of investigational vonapanitase during surgical creation of a radiocephalic fistula for hemodialysis may improve fistula use for hemodialysis and secondary patency (time to fistula abandonment), thereby improving patient outcomes and reducing the burden on patients and the healthcare system. Arteriovenous fistu...

GALE: Galena Biopharma Analysis and Research Report

2018-06-11 - Asif

Overview Galena Biopharma is a clinical-stage biopharmaceutical company focused on novel cancer immunotherapeutics for a broad range of cancer indications. The company's lead product candidate, galinpepimut-S, or GPS, is a cancer i unotherapeutic agent licensed from Memorial Sloan Kettering Cancer Center, or MSK, that targets the Wilms tumor 1, or WT1, protein, which is present in 20 or more cancer types. Based on its mechanism of action as a directly immunizing agent, GPS has the potential as a monotherapy or in combination with other immunotherapeutic agents to address a broad spectrum of hematologic, or blood, cancers and solid tumor indications. Phase 2 clinical trials for GPS have been completed and Galena Biopharma has planned Phase 3 clinical trials (pending funding availability) for two indications, acute myeloid leukemia, or AML, and malignant pleural mesothelioma, or MPM. GPS is also in development as a potential treatment for multiple myeloma, or MM, and ovarian can...

CUSIP: 00434H108